+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antidiabetics Market Size, By Product, By Patient Population, By Route of Administration, By Region, Trend Analysis, Market Competition Scenario & Outlook, 2020-2026

  • PDF Icon


  • 175 Pages
  • August 2020
  • Region: Global
  • Blueweave Consulting & Research Pvt Ltd
  • ID: 5146283
The Global Antidiabetics Market to Grow Substantially and Reach USD 121.4 Billion by 2026

According to the publisher, The Global Antidiabetics Market was valued at USD 63.5 billion in 2019 and is expected to reach USD 121.40 billion in 2026, at a CAGR of 9.7% during the forecast period.

The increasing risk of diabetes across all age-group worldwide, need for medication without substantial side effects and increasing R&D outlays of the pharmaceutical companies drive the growth of this market. The complete treatment for diabetes has become the focal point of care due to the burgeoning diabetic population across all age-groups including children. The anti-diabetics market developed immensely in the recent years due to growing occurrence of diabetes mellitus and, is expected to expand substantially due to its mounting demand and acceptance in developing and developed nations during the forecast period.

Diabetes is a chronic metabolic disease wherein the body is either unable to produce insulin (Type-1) or cannot absorb the manufactured insulin (Type-2). The diabetic individual suffers from high blood glucose (blood sugar) and experience symptoms such as grown thirst (polydipsia), weight loss, increased hunger (polyphagia), and recurrent and sweet-smelling urination (polyuria). If such symptoms are not appropriately addressed, diabetes can cause severe and chronic life-threatening complications.

Any person irrespective of age or gender may suffer from diabetes at any point in life. The obese people and the individuals with unhealthy diets and less physical activity are more prone to diabetes. Diabetes may lead to critical ailments such as sightlessness, amputations, kidney failure, and advanced risk of death.

The Antidiabetic Market is segmented based on Product, Administration Route, Patient Age-group and into Insulin segment and Drug segment based on product. Based on Product, the market is subdivided into Insulin Products and Drugs while based on Route of Administration, it is divided into Syringe/Pen, Insulin Pump, Intravenous Infusion and Oral.

“The Insulin Products segment and Insulin-Pump segment hold the major market share.”

The Insulin Product segment leads the antidiabetic market, followed by Drug segment. It secured a notable market share in 2019 and, is anticipated to continue the same at a remarkable CAGR of 12.4% during the forthcoming period due to its high success rate. Besides, short-acting analogue in this segment has improved glucose-controlling ability in Type 1 and Type 2 diabetes. The segment is expected to witness unparalleled growth due to surge in diabetes-2 patients.

In category of Administration route, the Insulin pumps segment dominates the market and is expected to grow at significant CAGR of 11 % due to the advantages and convenience of its use during the period 2020-2026. It allows less chance of severe glycaemic conditions with less glucose variability and, stores data that can be further used in analysis and treatment scheduling.

“The Key Drivers of the Antidiabetics Market are Growing investment in Drug development and Prevalence of Diabetes across the world.”

According to the European Society of Cardiology, Diabetic population size will reach 628.6 million by 2045, as per the study of European Society of Cardiology. The diabetic treatment needs appropriate interference and administration of medicines while taking care of patients. Progression in antidiabetic drugs has amplified success rates and reduced difficulties.

Various new drugs such as dipeptidyl peptidase-4 inhibitors, discriminatory sodium-glucose cotransporter 2 inhibitors, and exclusive peroxisome proliferator-activated receptor agonists are in growth stages. Besides new devices have been introduced, improving chances for effective combination treatments. Also, public and structural efforts for innovations in diabetes drugs space induce the market for the time being.

The number of diabetic patients has increased due to sedentary lifestyles, obesity, the rise in geriatric populations and inadequate healthcare services across the globe, propelling growth for antidiabetic market.

However, high cost of insulin may limit Antidiabetic Market development to some degree in emerging countries.

“North America dominates the Antidiabetics Market.”

North America market retains the major market share and is anticipated to preserve it with modest CAGR on account of advancements, better healthcare infrastructure, high spending on healthcare, promising repayment policies, and prevalent use of long-acting and fast-acting insulin equivalents in nations of this region. The Asia Pacific is expected to observe substantial growth during the projection period due to government initiatives, increasing healthcare outlays as well increasing Type I and Type II diabetic population.

Some of the “Leading players” operating in the Global Antidiabetics Market are Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

This product will be delivered within 2 business days.

Table of Contents

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Patient Populations
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Primary & Secondary Patient Populations
2.3.2. Secondary Research
2.3.3. Primary Research
2.4. Breakdown of Primary Research Respondents, By Region
2.5. Assumption & Limitation
3. Executive Summary
4. Global Antidiabetics Industry Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape/Recent Development
4.4. Company Market Share Analysis, 2019
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
4.6. Regulatory Framework
4.7. Company Market Share Analysis, 2019
4.8. Porter’s Five forces analysis
4.9. Impact of Covid-19 on Global Antidiabetics Industry.
5. Global Antidiabetics Market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product Type Insulin Rapid Acting Long Acting Premixed Insulin Short-Acting Intermediate Acting
5.2.2. By Drug Class Alpha-Glucosidase Inhibitors Biguanides Sulphonylureas GLP-1 Agonist Meglitinides DPP-4 Inhibitors SGLT-2 Thiazolidinedione
5.2.3. By Patient Population Pediatric Adult Geriatric
5.2.4. By Route of Administration Insulin Syringe/Insulin Pen Insulin Pump Intravenous Infusion Oral
5.2.5. By Region North America Europe Asia Pacific Latin America Middle East & Africa
6. North America Antidiabetics Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Route of Administration Industry
6.2.2. By Product Type
6.2.3. By Drug Class
6.2.4. By Patient Population Type
6.2.5. By Country United States Canada
7. Europe Antidiabetics Market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Route of Administration Industry
7.2.2. By Drug Class
7.2.3. By Product Type
7.2.4. By Patient Population Type
7.2.5. By Country Germany United Kingdom France Italy Spain Rest of Europe
8. Asia Pacific Antidiabetics Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Route of Administration Industry
8.2.2. By Drug Class
8.2.3. By Product Type
8.2.4. By Patient Population Type
8.2.5. By Country China India Japan Rest of Asia Pacific
9. Latin America Antidiabetics Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Route of Administration Industry
9.2.2. By Drug Class
9.2.3. By Product Type
9.2.4. By Patient Population Type
9.2.5. By Country Brazil Mexico Argentina Rest of Latin America
10. Middle East & Africa Antidiabetics Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Route of Administration Industry
10.2.2. By Drug Class
10.2.3. By Product Type
10.2.4. By Patient Population Type
10.2.5. By Country Saudi Arabia UAE South Africa Rest of Middle East & Africa
11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
11.1. Astra Zeneca plc
11.2. Boehringer Ingelheim GmbH
11.3. Eli Lilly & Co.
11.4. Johnson & Johnson
11.5. Mankind Pharma Ltd.
11.6. Merck & Co. Inc.
11.7. Novartis AG
11.8. Novo Nordisk A/S
11.9. Sanofi S.A.
11.10. Teva Pharmaceutical Industries Ltd.
11.11. Other Prominent Players
* Financial details in case of unlisted companies will be available as per data availability**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astra Zeneca plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Johnson & Johnson
  • Mankind Pharma Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • SanofiS.A.
  • Teva Pharmaceutical Industries Ltd.